CVS Health
CVS HEALTH CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$402.1B
Operating marginCalculated
1.2%
Net assets to total assetsCalculated
29.7%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
1.2%
Growth (revenue, 4-year average)
★★★★☆position among all companies
8.3%
Capital efficiency
★★☆☆☆position among all companies
2.4%
Revenue and profit
Performance, financial position and capital allocation
CVS Health
Recent performance trends
CVS Health
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$292.1 billion | US$322.5 billion | US$357.8 billion | US$372.8 billion | US$402.1 billion |
| Operating income | US$13.3 billion | US$8.0 billion | US$13.7 billion | US$8.5 billion | US$4.7 billion |
| Net income | US$8.0 billion | US$4.3 billion | US$8.3 billion | US$4.6 billion | US$1.8 billion |
| Total assets | US$233.0 billion | US$228.3 billion | US$249.7 billion | US$253.2 billion | US$253.5 billion |
| Shareholders' equity | US$75.1 billion | US$71.5 billion | US$76.5 billion | US$75.6 billion | US$75.2 billion |
| Net cash provided by (used in) operating activities | US$18.3 billion | US$16.2 billion | US$13.4 billion | US$9.1 billion | US$10.6 billion |
| Net cash provided by (used in) investing activities | US$-5.3 billion | US$-5.0 billion | US$-20.9 billion | US$-7.6 billion | US$-5.9 billion |
| Net cash provided by (used in) financing activities | US$-11.4 billion | US$-10.5 billion | US$2.7 billion | US$-1.1 billion | US$-4.9 billion |
| Cash and cash equivalents | US$9.4 billion | US$12.9 billion | US$8.2 billion | US$8.6 billion | US$8.5 billion |
Revenue scale in the same industry
CVS Health
Other retail: 18 companies · revenue · largest first・FY Dec 2025・Consolidated・Disclosed
- 1 AMAZON.com US$716.9B
- 2 CVS HealthThis company US$402.1B
- 3 Coupang US$34.5B
- 4 CDW US$22.4B
- … 14 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$2.8 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$8.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-4.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-5.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$10.6 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$4.6 billion | Consolidated | Disclosed |
| Dividends paid | US$3.4 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$75.4 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.2 billion | Consolidated | Disclosed |
| Net assets | US$75.2 billion | Consolidated | Disclosed |
| Net sales | US$402.1 billion | Consolidated | Disclosed |
| Operating income | US$4.7 billion | Consolidated | Disclosed |
| Net income | US$1.8 billion | Consolidated | Disclosed |
| Total assets | US$253.5 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0 | Consolidated | Disclosed |
| Operating margin | 1.2% | Consolidated | Calculated |
| Net assets to total assets | 29.7% | Consolidated | Calculated |
| Net margin | 0.4% | Consolidated | Calculated |
| Return on equity | 2.4% | Consolidated | Calculated |